Semaglutide vs Tirzepatide vs Retatrutide: What the Research Actually Shows

By the Peptigo Research Team · Published April 2026 · Last reviewed April 23, 2026 · 15 minute read

The incretin pharmacology field has moved faster in the past decade than at any point in its history. Semaglutide arrived as a single-receptor GLP-1 agonist. Tirzepatide added a second receptor target. Retatrutide, still in late-phase clinical trials, engages three. Each step outward in receptor coverage has produced larger metabolic-research signals in the published literature, though the biology behind that progression is more complicated than a simple “more targets, better outcomes” framework suggests. This article traces the mechanistic differences between the three compounds, covers what the peer-reviewed trial data actually show, and explains the engineering decisions behind the dual- and triple-agonist designs.

This is a research-focused reference, not a prescribing guide. Peptigo supplies all three compounds strictly for in vitro research use. The regulatory and clinical framing in this article reflects the published scientific literature and is context for understanding the research compounds — nothing here is medical advice.

GLP-1, GIP, and Glucagon Receptor Biology

Three G-protein-coupled receptors sit at the center of this discussion. Understanding what each one does when activated clarifies why researchers added a second and then a third target.

GLP-1 Receptor (GLP-1R)

Glucagon-like peptide-1 is an incretin hormone secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. GLP-1R activation in the pancreas potentiates glucose-dependent insulin secretion and suppresses glucagon release. In the central nervous system — particularly the hypothalamus, brainstem, and nucleus accumbens — GLP-1R signaling reduces appetite and slows gastric emptying. The receptor is a class B GPCR that signals primarily through the Gs-adenylyl cyclase-PKA pathway. It is the best-characterized of the three receptors in this family and has the longest incretin-pharmacology research history.

GIP Receptor (GIPR)

Glucose-dependent insulinotropic polypeptide is the other major incretin hormone, secreted by K-cells in the proximal small intestine. GIPR activation potentiates insulin secretion in a glucose-dependent manner, similar to GLP-1R, but also has adipose-tissue and CNS effects that GLP-1R does not share cleanly. The GIP pathway was historically considered less pharmacologically useful than GLP-1 because early work suggested the receptor became less responsive in metabolic-disease states. The current understanding, shaped largely by tirzepatide research, is more nuanced — GIPR activation appears synergistic with GLP-1R activation in contexts where single-receptor work predicted a smaller signal.

Glucagon Receptor (GCGR)

Glucagon is traditionally the counter-regulatory hormone to insulin, raising blood glucose in response to fasting. That framing alone makes GCGR activation look like the wrong pharmacological target for metabolic-disease research. The reason retatrutide adds GCGR activity is that glucagon receptor activation in the liver also drives fatty acid oxidation and, when combined with GLP-1 and GIP agonism, produces a metabolic phenotype that single- and dual-receptor agonism do not. The liver-metabolic effects of GCGR activation are the piece of the retatrutide rationale worth understanding.

Semaglutide: The Single GLP-1 Agonist

Semaglutide is a 31-residue GLP-1 analogue engineered to survive plasma long enough to be useful. Native GLP-1 has a half-life measured in minutes because it is cleaved rapidly by dipeptidyl peptidase IV. Semaglutide’s half-life extends past 165 hours, which changes the protocol landscape entirely. The engineering is three pieces: an Aib8 substitution that blocks DPP-IV cleavage at the vulnerable N-terminal site, an Arg34 substitution that reduces a second clearance pathway, and a C18 fatty diacid linker that binds serum albumin and tethers the peptide to a carrier protein large enough to slow renal filtration.

Lau et al. (2015) is the discovery and characterization paper for semaglutide, published in the Journal of Medicinal Chemistry. The receptor pharmacology is classical: GLP-1R binding on pancreatic beta cells and extra-pancreatic tissues including CNS, stomach, and cardiovascular tissues, with Gs-adenylyl cyclase-PKA downstream signaling. The clinical research base is among the deepest of any GLP-1 agonist; Knudsen (2019, Frontiers in Endocrinology) is the accessible review for researchers entering the literature from outside incretin pharmacology.

The SUSTAIN and STEP trial series are the main reference datasets for human pharmacology with semaglutide, covering both weekly subcutaneous dosing in metabolic research and CV-outcome research. Kapitza et al. (2015) and Nauck et al. (2016) examined pharmacokinetic profiles across dose ranges. For research-compound users, the practical point is that semaglutide is the most thoroughly characterized single-receptor GLP-1 agonist and is the standard reference compound when comparing newer agents in the incretin class.

Tirzepatide: The Dual GLP-1 / GIP Agonist

Tirzepatide is a single 39-residue peptide that agonizes two receptors. Dual-receptor peptide design had been a research goal for years before tirzepatide made it work at scale. The sequence is derived from the native GIP backbone with selected substitutions that confer GLP-1 receptor cross-reactivity. A C20 fatty diacid linker handles the albumin-binding half-life extension, producing a roughly five-day plasma half-life.

The interesting question about tirzepatide is not what it does but how the affinity ratio was engineered. Tirzepatide binds GIPR at an affinity approaching native GIP and binds GLP-1R at roughly five-fold lower affinity than native GLP-1. That asymmetry is deliberate. Willard et al. (2020) characterized the differential affinities in more structural detail; Coskun et al. (2018, Molecular Metabolism) is the discovery paper and the standard reference for the design rationale.

The SURPASS and SURMOUNT trial series are the human pharmacology dataset for tirzepatide. Frias et al. (2021, NEJM) reported the dose-response pharmacology that established tirzepatide as a distinct compound from the single-receptor class. Min and Bain (2021) reviewed the dual-agonist pharmacology at the class level, and El et al. (2023, Peptides) is worth reading alongside Willard for a mechanistic comparison of tirzepatide and semaglutide that goes beyond the raw binding numbers to receptor residence times and signaling bias.

Retatrutide: The Triple GLP-1 / GIP / Glucagon Agonist

If tirzepatide is a dual agonist, retatrutide is the answer to the obvious next question: what happens if you add a third receptor. Retatrutide is another 39-residue peptide, engineered to hit GLP-1, GIP, and glucagon receptors with a defined affinity ratio. The glucagon receptor component is the new piece, and it is what makes retatrutide a distinct research question rather than a semantic extension of the tirzepatide class.

Each of the three receptors signals through Gs-adenylyl cyclase-PKA. The glucagon receptor additionally couples to Gq and phospholipase C, which is the piece that differentiates retatrutide pharmacology from dual-GLP-1/GIP work. Adding glucagon receptor activity is not a simple additive effect — the hepatic response to GCGR activation brings metabolic inputs that the GIP and GLP-1 axes alone do not cover. This is the reason retatrutide produces signals in metabolic-research contexts that even tirzepatide does not fully replicate.

Coskun et al. (2022, Cell Metabolism) is the pivotal discovery and characterization paper. Jastreboff et al. (2023, NEJM) examined dose-response pharmacokinetics in a Phase 2 research context and reported 24.2% mean body-composition changes at 48 weeks along with notable liver-fat reductions. Rosenstock et al. (2023) covered additional pharmacokinetic profiles. Phase 3 trials are ongoing as of 2026, and the compound is not yet approved for clinical use — it remains a research compound in active late-phase development.

Why Researchers Care About the Differential Receptor Affinities

The binding-affinity numbers for dual and triple agonists are more than a design curiosity. They shape every question a research protocol can ask about these compounds.

Consider tirzepatide. Its GIP affinity approaches native GIP, but its GLP-1 affinity is five-fold lower than native GLP-1. In a research context comparing tirzepatide to semaglutide on a purely GLP-1-mediated endpoint, that affinity gap matters: at equivalent molar doses, tirzepatide engages GLP-1R less than semaglutide does. The observed metabolic-research differences between the two compounds are therefore not explainable by “tirzepatide hits GLP-1 harder.” They are explainable by the synergistic effect of dual-receptor engagement, where GIPR activation amplifies the downstream consequence of a lower-affinity GLP-1R hit.

Retatrutide adds a further complication. Its glucagon receptor affinity is tuned specifically to engage hepatic GCGR without producing a counter-regulatory hyperglycemic signal that would negate the GLP-1 and GIP contributions. This is a narrow engineering window. Coskun et al. (2022) addressed it by characterizing the receptor-residence-time and signaling-bias properties of retatrutide at each receptor, which together produce a pharmacology profile different from any combination of the individual single-agonist parents.

For research-protocol design, the practical implication is that dual- and triple-agonist compounds are not interchangeable with stacks of single-agonist components. The affinity ratios embedded in the engineered peptides produce downstream biology that the separate components, dosed independently, do not reproduce. Protocol design that models tirzepatide as “semaglutide plus a GIP agonist” will generate misleading data.

Comparison at a Glance

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1R	GLP-1R + GIPR	GLP-1R + GIPR + GCGR
Residues	31	39	39
Half-life linker	C18 fatty diacid	C20 fatty diacid	C20 fatty diacid
Plasma half-life	~165 hours	~5 days	Multi-day, sustained
Relative GLP-1R affinity	Reference (1x)	~5-fold lower	Engineered balance
Clinical status (2026)	Rx (Ozempic/Wegovy)	Rx (Mounjaro/Zepbound)	Phase 3
Discovery paper	Lau et al. 2015	Coskun et al. 2018	Coskun et al. 2022
Key Phase 2/3 paper	Kapitza 2015, SUSTAIN/STEP	Frias 2021 (SURPASS)	Jastreboff 2023

Research Considerations: Selecting the Right Compound for a Given Model

For researchers designing incretin-pharmacology studies, the compound choice is not arbitrary. Each of the three has a specific role depending on the research question.

Semaglutide is the right reference compound when the research question is about GLP-1R biology in isolation. Its single-receptor selectivity makes it useful for mechanism studies where receptor specificity is the variable being controlled. It is also the compound with the longest and deepest human-data base, which makes it the best choice for protocols that need to reference extensive prior pharmacological characterization.

Tirzepatide is the right choice when the research question involves GIPR biology, GIP-GLP-1 synergy, or the pharmacology of dual-agonist engineering itself. It is the standard reference for any protocol examining how differential receptor affinities shape downstream signaling.

Retatrutide belongs in protocols examining GCGR biology in conjunction with incretin signaling, particularly hepatic metabolic pathways. It is also the compound of choice for research on triple-receptor engineering as a design paradigm. Because it is still in late-phase clinical development, the research literature on it is smaller than for the other two — which makes it a good candidate for mechanism research where the literature gaps themselves are the research opportunity.

The Manufacturing and Supply Context in 2026

Any 2026 discussion of this compound class has to address the manufacturing and supply story. Semaglutide and tirzepatide have been under shortage pressure since 2023 as demand for the branded formulations (Ozempic, Wegovy, Mounjaro, Zepbound) outpaced manufacturing capacity. The FDA’s shortage-list status for both compounds opened a 503A compounding pathway that expanded the non-branded supply chain substantially.

The 2024-2025 period saw the FDA move both compounds off the shortage list, which closed the compounding-pharmacy door for branded-equivalent formulations. That regulatory shift has consequences for research-grade supply as well: the quality variance across suppliers of research-grade incretin peptides is substantial, and sourcing decisions in 2026 should weight third-party lab verification and COA transparency more heavily than was common when compounding supply was abundant.

For research procurement, the baseline quality expectation is independent third-party HPLC-UV purity verification, LC-MS identity confirmation, and standard sterility and endotoxin testing. Peptigo ships every batch with a Janoshik Analytical COA covering that full panel. Retatrutide supply is a separate story — it is not yet an approved drug, and research-grade retatrutide in 2026 comes through a narrower supplier base with correspondingly more variability in characterization quality. Protocol design using retatrutide should build in batch-level QC that is less critical with the other two compounds.

Research Frontiers

The incretin class is not finished evolving. Four threads of current research are worth knowing.

Beyond triple agonism. Quad-agonist designs that add amylin receptor engagement are in preclinical development. Cagrilintide-semaglutide combination research is the current most-advanced research in this direction. The question is whether quad-receptor engagement crosses a complexity threshold where the affinity-ratio engineering becomes infeasible.

Oral formulations. Oral semaglutide exists in clinical form (Rybelsus) but has an absorption bioavailability problem that limits its utility. Research into permeation-enhancer formulations and alternate peptide backbones is active. The broader research question is whether the incretin class can move off injection entirely without losing pharmacokinetic stability.

Tissue-specific signaling bias. The three receptors in this class each couple to multiple downstream pathways (Gs, Gq, beta-arrestin). Engineered agonists that bias signaling toward specific downstream effectors are an active research frontier, with the goal of isolating the therapeutically relevant signaling from the full receptor-activation profile.

CNS pharmacology. The appetite-regulation effects of GLP-1 and related agonists appear to run through specific hypothalamic and brainstem circuits. CNS-expression-pattern research on GLP-1R, GIPR, and GCGR is refining the mechanism map and suggesting that the therapeutic effects of incretin agonists may be more CNS-driven than the early pancreatic-focused pharmacology suggested.

The Cardiovascular Outcomes Angle

One of the less-obvious aspects of the semaglutide research base is that cardiology has become heavily invested in this compound class. The SELECT trial (semaglutide, published 2023-2024) reported cardiovascular-event-reduction signals in research populations without prior metabolic-disease diagnosis. That result repositioned semaglutide in the pharmacological landscape — the compound is no longer primarily framed as a metabolic-disease agent, but as a cardiovascular-outcomes agent whose effects extend beyond glycemic control.

For researchers, the CV-outcomes framing matters in two ways. First, it suggests that GLP-1R signaling has direct vascular effects independent of glycemic pathway changes. The mechanism work on this is active: GLP-1R is expressed in cardiovascular tissue, and receptor activation there appears to modulate inflammation, endothelial function, and possibly plaque biology through pathways that are not obviously downstream of insulin or appetite regulation. Second, the CV-outcomes data shapes the comparison with tirzepatide and retatrutide. The SURPASS-CVOT and retatrutide Phase 3 cardiovascular trials will generate the datasets that establish whether the dual- and triple-agonist compounds replicate the CV-outcome signal semaglutide produced, exceed it, or diverge from it.

The broader research point: the incretin class has moved out of endocrinology-only research and into cardiology, hepatology, and neurology simultaneously. Protocol design that frames these compounds as narrow metabolic-research tools is increasingly out of step with where the clinical literature has gone.

Reading the Primary Literature: What Actually Rewards Careful Study

For researchers entering the incretin-class literature, a handful of papers reward the time investment far more than the rest. A curated short list:

For mechanism. Lau et al. 2015 (semaglutide discovery), Coskun et al. 2018 (tirzepatide discovery), and Coskun et al. 2022 (retatrutide discovery) are the three papers that define the design rationale for each compound. Reading them in sequence makes the progression of incretin engineering legible in a way no review article captures.

For structural pharmacology. Willard et al. 2020 on tirzepatide’s differential receptor affinities is the paper that shifted the dual-agonist conversation from “more receptors is better” to “affinity ratios are the design variable.” El et al. 2023 is the accessible mechanistic comparison of tirzepatide and semaglutide and is worth reading alongside Willard for the signaling-bias piece.

For human pharmacology. Frias et al. 2021 (SURPASS dose-response) is the tirzepatide reference. Jastreboff et al. 2023 (retatrutide Phase 2) is the retatrutide reference. Kapitza et al. 2015 anchors the semaglutide pharmacokinetic base, though the SUSTAIN and STEP trial program is where the modern semaglutide human-data understanding actually lives.

For class-level framing. Knudsen 2019 is the readable GLP-1 class review. Min and Bain 2021 is the dual-agonist class review. Neither is a replacement for the primary papers, but both are useful orientation for researchers who need the class context before diving into compound-specific mechanism work.

Open Questions in the Incretin Class

A research field this active is defined as much by its open questions as by its settled findings. Four questions stand out in 2026.

How much of the metabolic effect is central vs peripheral? The canonical framing emphasizes pancreatic insulin secretion and gut-level incretin signaling. The CNS-mediated appetite-regulation mechanism is increasingly central to the current understanding, and the open research question is what fraction of the observed clinical signal is peripheral vs central. Protocol design that assumes a single answer will be wrong for at least some endpoints.

What is the durability of the effect after compound discontinuation? The available human data suggests significant regression toward baseline after discontinuation, which raises mechanistic questions about whether the compounds produce structural metabolic change or ongoing pharmacological modulation. The answer has consequences for both research protocol duration and the broader clinical-use framing.

How far does the receptor-engagement scaling go? Single to dual to triple agonism has produced sequentially larger signals. Whether quad agonism (adding amylin) crosses a diminishing-returns threshold is the next empirical question. Cagrilintide-semaglutide combination research is one line of evidence; quad-agonist single-molecule designs are another.

What is the tissue-specific receptor landscape for GCGR? Glucagon receptor biology is better-characterized in the liver than in other tissues, and the metabolic effects of GCGR activation in adipose, skeletal muscle, and CNS are active research areas. Retatrutide’s pharmacology depends on the answers, and the data base is still developing.

Shop the compounds in this comparison

All three are supplied by Peptigo as research-grade reference compounds with Janoshik third-party testing. Browse current batch COAs:

Buy Semaglutide in Canada — single GLP-1 receptor agonist

Buy Tirzepatide in Canada — dual GLP-1 / GIP agonist

Buy Retatrutide in Canada — triple GLP-1 / GIP / glucagon agonist (research-grade only; Phase 3)

Reconstitution Notes for Research Use

All three compounds are supplied by Peptigo as lyophilized powder. Reconstitution uses bacteriostatic water as the standard diluent. The Peptigo reconstitution calculator handles the volume and concentration arithmetic for a given target research dose. Reconstituted peptide stability is the main practical concern for laboratory handling: refrigerated storage at 2-8°C and protection from light are standard, with a typical functional window of four to six weeks post-reconstitution.

For any of these compounds, protocol design should specify vehicle composition and reconstitution timing explicitly. The half-life differences across the three compounds mean the effective concentration in a research assay depends significantly on when the dose was prepared relative to when it was administered. Documenting this step is part of reproducibility hygiene that the incretin-research literature takes seriously.

References

Lau J, et al. Journal of Medicinal Chemistry. 2015. (Semaglutide discovery and characterization)
Kapitza C, et al. 2015. (Semaglutide pharmacokinetics)
Nauck MA, et al. 2016. (Semaglutide dose-response pharmacology)
Knudsen LB. Frontiers in Endocrinology. 2019. (GLP-1 analogue class review)
Coskun T, et al. Molecular Metabolism. 2018. (Tirzepatide discovery)
Willard FS, et al. 2020. (Tirzepatide differential receptor affinities)
Frias JP, et al. NEJM. 2021. (Tirzepatide SURPASS dose-response)
Min T, Bain SC. 2021. (Dual-agonist pharmacology review)
El K, et al. Peptides. 2023. (Tirzepatide vs semaglutide mechanistic comparison)
Coskun T, et al. Cell Metabolism. 2022. (Retatrutide discovery)
Jastreboff AM, et al. NEJM. 2023. (Retatrutide Phase 2 pharmacokinetics)
Rosenstock J, et al. 2023. (Retatrutide additional pharmacokinetic profiles)
PubMed references: tirzepatide · semaglutide · retatrutide

Disclaimer: This article is a research-literature overview for educational purposes. Nothing here is medical advice. All Peptigo products are sold strictly for laboratory and research use only. Not for human or veterinary use.